eccogene glp-1 Eccogene obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases GLP-1 Analogues Market Size to

The 10 and 15 mg doses of tirzepatide significantly reduced the number of large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP), and the LPIR score compared to both the placebo and dulaglutide

Niacinamide (Vitamin B3) Niacinamide strengthens the skin barrier, minimizes pores, balances oil production, and improves uneven skin tone

The gut-skin axis is not a new-age concept

and Semax, a supposed form of migraine relief

Effectiveness and safety of combining SGLT2 inhibitors and GLP1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies